Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.52 |
| ▸ | KDM1A | O60341 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23140795 | 0.99 | HTR2C (0.54) | HTR2CKDM1AHTR2AHTR2BDRD2 | |
| SCHEMBL21296536 | 0.80 | HTR2C (0.49) | HTR2CHTR2AHTR2BDRD2 | |
| SCHEMBL23140838 | 0.80 | NOTUM (0.40) | — | |
| SCHEMBL23140857 | 0.80 | HTR2C (0.49) | HTR2CKDM1AHTR2AHTR2BDRD2 | |
| SCHEMBL20063931 | 0.80 | HTR2C (0.49) | HTR2CHTR2AHTR2BDRD2 | |
| SCHEMBL31495941 | 0.80 | HTR2C (0.49) | HTR2CKDM1AHTR2AHTR2BDRD2 | |
| SCHEMBL1065758 | 0.79 | HTR2C (0.77) | HTR2CKDM1AHTR2AHTR2BDRD2 | |
| Hydrochloric Acid SCHEMBL23140831 | 0.79 | NOTUM (0.39) | HTR2C | |
| SCHEMBL15336102 | 0.79 | HTR2C (0.66) | HTR2CKDM1AHTR2AHTR2BDRD2 | |
| SCHEMBL22816107 | 0.79 | HTR2C (0.66) | HTR2CHTR2AHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3797101-A1 | PYRIDIDNE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| CN-112041313-A | Pyridine-sulfonamide compounds and their use against pain and related conditions | 基因泰克公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2019165290-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | GENENTECH, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | HTR2C 2475/4885KDM1A 4612/4885HTR2A 3363/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | HTR2C 823/4885KDM1A 3431/4885HTR2A 1341/4885 |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | HTR2C 1243/4885KDM1A 2698/4885HTR2A 2222/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | HTR2C 1243/4885KDM1A 2698/4885HTR2A 2222/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | HTR2C 823/4885KDM1A 3431/4885HTR2A 1341/4885 |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | SCN1B, CACNA1A, SCN1A | HTR2C 1626/4885KDM1A 1140/4885HTR2A 1515/4885 |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, CACNA1A, SCN1A | HTR2C 1563/4885KDM1A 1223/4885HTR2A 1421/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | HTR2C 1184/4885KDM1A 2873/4885HTR2A 2099/4885 |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | F12, REN, ZYX | HTR2C 2002/4885KDM1A 2946/4885HTR2A 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.